Drugs / SRSD216
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07172646 | Apr 2025 → May 2026 overdue | hyperlipoproteinemia | Sirius Therapeutics Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SRSD216 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07172646 ↗ |
| Route | Subcutaneous | “Administered SC.” NCT07172646 ↗ |